

## J&J gives data to support boosting its single-shot COVID-19 vaccine

25 August 2021 | News

## New studies build on data demonstrating strong durability through eight months after immunization



Johnson & Johnson (J&J) has announced data supporting the use of its COVID-19 vaccine as a booster shot for people previously vaccinated with the single-shot Johnson & Johnson vaccine.

In July, the Company reported interim Phase 1/2a data published in the New England Journal of Medicine that demonstrated neutralizing antibody responses generated by the Johnson & Johnson single-shot COVID-19 vaccine were strong and stable through eight months after immunization.

In anticipation of the potential need for boosters, the company conducted two Phase 1/2a studies in individuals previously vaccinated with its single-shot vaccine.

New interim data from these studies demonstrate that a booster dose of the Johnson & Johnson COVID-19 vaccine generated a rapid and robust increase in spike-binding antibodies, nine-fold higher than 28 days after the primary single-dose vaccination.

Significant increases in binding antibody responses were observed in participants between ages 18 and 55, and in those 65 years and older who received a lower booster dose. The study summaries were submitted to medRxiv onAugust 24.

The company is engaging with the U.S. Food and Drug Administration (FDA), U.S. Centers for Disease Control and Prevention (CDC), European Medicines Agency (EMA) and other health authorities regarding boosting with the Johnson & Johnson COVID-19 vaccine.